BVF, with other PIPE Investors, agreed to purchase approximately 3,154,241 shares of Pieris common stock and/or Pre-Funded Warrants in the PIPE Financing under a Purchase Agreement dated July 23, 2024
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Wesley H. Kaupinen
Also a director
President, Chief Executive Officer and Director
|
48 | Not stated | $3,404,904 | |
|
Matthew E. Korenberg
Chief Financial Officer, Treasurer and Secretary
|
Not stated | Not stated | $1,971,437 | |
|
Kathleen Goin
Chief Operating Officer
|
Not stated |
Since 2024
2 years
|
$1,979,837 | |
|
Jeffrey Martini
Chief Scientific Officer
|
Not stated |
Since 2024
2 years
|
Not reported | |
|
Ashley Kline
Chief Commercial Officer
|
Not stated |
Since 2025
1 year
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Jun 30, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Wesley H. Kaupinen
CEO
|
48 |
2024
2 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
George M. Jenkins
|
74 |
2024
2 years
|
Not stated |
Audit · Chair
Compensation
|
None stated | $303,255 | |
|
Todd C. Davis
|
65 |
2024
2 years
|
Not stated |
Compensation · Chair
Nominating and Corporate Governance
|
Ligand Pharmaceuticals Incorporated, Pelthos Therapeutics Inc. | $269,755 | |
|
John Doux
|
57 |
2026
this year
|
Not stated | None stated | None stated | Not stated | |
|
Christopher Kiritsy
|
61 |
2016
10 years
|
Not stated |
Audit
Nominating and Corporate Governance
|
None stated | $267,255 | |
|
Elaine J. Heron, Ph.D.
|
78 |
2024
2 years
|
Not stated |
Audit
Nominating and Corporate Governance · Chair
|
Vaxart, Inc. | $271,255 | |
|
Tadd S. Wessel
|
50 |
2024
2 years
|
Not stated |
Compensation
Nominating and Corporate Governance
|
None stated | $264,755 | |
|
Matthew Pauls
Joined Jun 29, 2026
|
- | - | Independent | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
BVF, with other PIPE Investors, agreed to purchase approximately 3,154,241 shares of Pieris common stock and/or Pre-Funded Warrants in the PIPE Financing under a Purchase Agreement dated July 23, 2024
Indemnification agreements between Pieris and each of its directors and executive officers
Loading...